- Company
- New HIV drug Biktarvy sales of ₩20 billion in one year
- by Kim, Jin-Gu Aug 31, 2020 05:58am
- It is confirmed that Gilead Science's new HIV treatment, Biktarvy, made close to &8361;20 billion in a year after it entered the market in earnest. According to the analysis, Gilead is maintaining the leadership in the HIV treatment market due to the rapid growth of Biktarvy. ◆Biktarvy, sales of &8361;14.4 billion in the first half of
- Company
- Sanofi Pasteur Korea welcomes new GM Pascal Robin
- by Eo, Yun-Ho Aug 31, 2020 05:57am
- The newly appointed general manager at Sanofi Pasteur Korea, Pascal Robin has started his work in the office from Aug. 25. According to the company, General Manager Pascal Robin has been successfully serving various executive-level positions for over two decades in pharmaceutical industry distribution management, strategy, management and
- Company
- Kadcyla passed deliberation for cancer maintenance therapy
- by Eo, Yun-Ho Aug 31, 2020 05:57am
- According to related industries, the Antibody-drug conjugate (ADC) Kadcyla (Trastuzumab emtansine) passed the cancer disease review committee of the HIRA (26th). The exact criteria for applying for an increase in benefits is 'post-operative adjuvant therapy for HER2-positive early breast cancer patients with invasive residual lesions after
- Company
- Venclexta passed the cancer disease review committee
- by Eo, Yun-Ho Aug 31, 2020 05:57am
- Anti-cancer drug Venclexta is in a hurry to expand the coverage to second-line leukemia therapy According to related industries, AbbVie's Venclexta (Venetoclax) was held yesterday (on the 26th) as a second-line combination therapy for relapsed, refractory chronic lymphocytic leukemia (CLL) that received previous treatments including at le
- Company
- Cancer Committee leaves Keytruda confused, now what?
- by Eo, Yun-Ho Aug 28, 2020 06:19am
- An immunotherapy Keytruda (pembrolizumab) indicated as a first-line treatment on lung cancer is still lost in a thick fog with its attempt to expand healthcare coverage. And it has been three years already. Health Insurance Review and Assessment Service’s (HIRA) Cancer Deliberation Committee was gathered on Aug. 26 to deliberate granti
- Company
- Sky Zoster has the highest market share ever
- by An, Kyung-Jin Aug 28, 2020 06:17am
- The shingles vaccine market successfully rebounded out of the affected area of COVID-19. Sky Zoster by SK Bioscience set a new record in market share by increasing market influence while sales of competitive products slowed. According to the drug market research agency IQVIA on the 28th, the size of the shingles prevention vaccine marke
- Company
- Obesity drug market expands despite COVID-19 as Qsymia soars
- by An, Kyung-Jin Aug 28, 2020 06:17am
- The obesity treatment market in South Korea has marked a significant growth in the first half of the year. The treatment market expanded, although the consumers became reluctant to open their wallets amid COVID-19 pandemic. A newcomer Qsymia is now leading the market alongside with Saxenda, or so-called ‘Gangnam Diet Shot.’ On Aug. 2
- Company
- The KRPIA appoints Kim Minyoung to succeed Kim Seongho
- by Eo, Yun-Ho Aug 28, 2020 06:17am
- Kim Seong-ho (62), the former executive director of the KRPIA, has been decided to succeed. According to related industries, KRPIA has recently confirmed Kim Min-young, who was in charge of the JAPAC regional headquarters (region) in Amgen Asia, as the general manager of insurance policy and external cooperation. The position is executive
- Company
- Janssen's investment in Lazertinib has scientific basis
- by An, Kyung-Jin Aug 27, 2020 06:25am
- Janssen, a global pharmaceutical company, is supporting the development of a new anticancer drug, 'Lazertinib,' introduced by Yuhan. Since the introduction of the technology in November 2018, a total of three global clinical trials have begun in a year and a half. In April, It showed its willingness to continue development by paying a large-s
- Company
- Champix has the lowest sales in 5 years
- by Kim, Jin-Gu Aug 27, 2020 06:24am
- Sales of Pfizer's stop-smoking aid, 'Champix (Varenicline)' declined. In the second quarter of this year, sales fell 26% compared to the previous quarter. Quarterly sales are the lowest since the third quarter of 2015. Despite the aggressive patent defense strategy, the number of applicants for the government's smoking cessation project st
